New chemo sequence aims to shrink pancreatic tumors enough for surgery
NCT ID NCT05825066
First seen Feb 01, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study is for people with pancreatic cancer that is either borderline or locally advanced, meaning it has not spread far but is hard to remove surgically. Researchers want to see if giving two different chemotherapy combinations one after the other can shrink the tumor enough to allow complete surgical removal. About 64 adults will receive gemcitabine plus nab-paclitaxel followed by mFOLFIRINOX, both already approved for advanced pancreatic cancer, but not yet tested in this sequence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.